Blog
RSS FeedPosted by Michael Wonder on 04 Mar 2022
PHARMAC updates access criteria for remdesivir
4 March 2022 - PHARMAC has heard from our expert advisors and clinicians treating people with COVID-19 that we need to ...
Posted by Michael Wonder on 01 Mar 2022
Kiwis call on Government to increase PHARMAC funding to help fund Spinraza treatment
1 March 2022 - A group of Kiwis are calling on the Government to increase PHARMAC funding to provide better ...
Posted by Michael Wonder on 28 Feb 2022
Flu vaccine price increase
1 March 2022 - PHARMAC has confirmed that the purchase price of the annual influenza vaccine will increase by $2 ...
Posted by Michael Wonder on 28 Feb 2022
New Zealand Pharmaceutical Schedule - 1 March 2022
1 March 2022 - The March 2022 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 28 Feb 2022
PHARMAC ensures earlier access to key COVID-19 treatment
28 February 2022 - The access criteria for remdesivir is being temporarily widened to allow hospitals to treat those with ...
Posted by Michael Wonder on 24 Feb 2022
Cystic fibrosis community disappointed with PTAC recommendations
23 February 2022 - New Zealand’s cystic fibrosis community received disappointing news today with a recommendation to PHARMAC that reduces ...
Posted by Michael Wonder on 23 Feb 2022
PHARMAC recommends funding cystic fibrosis medicine Trikafta but needs more funding
23 February 2022 - PHARMAC’s clinical experts are recommending cystic fibrosis drug Trikafta be funded for those aged over 12 ...
Posted by Michael Wonder on 23 Feb 2022
PHARMAC’s clinical experts recommend funding Trikafta
23 February 2022 - PHARMAC today announces its clinical advisory committee PTAC has recommended funding cystic fibrosis treatment Trikafta with ...
Posted by Michael Wonder on 16 Feb 2022
PHARMAC publishes experts’ advice and seeks views on access criteria for COVID-19 treatments
16 February 2022 - PHARMAC is releasing meeting records of its COVID-19 Treatments Advisory Group and seeking feedback on the patient ...
Posted by Michael Wonder on 14 Feb 2022
PHARMAC proposing to widen access to funded medicines
14 February 2022 - PHARMAC has issued a consultation today on proposals to widen access to two medicines, rituximab and zoledronic ...
Posted by Michael Wonder on 08 Feb 2022
Free EpiPen campaign returns in response to overwhelming demand
8 February 2022 - Allergy New Zealand and Pub Charity have relaunched the successful FundaPen campaign to deliver 3,355 free lifesaving ...
Posted by Michael Wonder on 31 Jan 2022
New Zealand Pharmaceutical Schedule - 1 February 2022 update
1 February 2022 - The Febuary 2022 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 27 Jan 2022
Shortage of prescription infant formula worries parents
28 January 2022 - A shortage of prescription infant formula has parents worried about how they will feed their babies. ...
Posted by Michael Wonder on 26 Jan 2022
Former bowel cancer patient calls for NZ to fund drug she says saved her life
26 January 2022 - A woman with bowel cancer who was told she may have two years to live says ...
Posted by Michael Wonder on 26 Jan 2022
PHARMAC confirms access criteria for COVID-19 treatments
26 January 2022 - PHARMAC has today confirmed the access criteria for two COVID-19 treatments – baricitinib and casirivimab with ...